home





























 

















 





















hrsa

participating institutions:
Johns Hopkins University AIDS Service, New York State DOH AIDS Institute, The CORE Center, Cook County Hospital



POST-EXPOSURE PROPHYLAXIS

last updated: June 29, 2001


COMPLETE GUIDELINES:


html pdf selected tables panel members


RELATED INFORMATION:


faqsnewslinks


References

  1. CDC. NIOSH alert: preventing needlestick injuries in health care settings. Cincinnati, OH: Department of Health and Human Services, CDC, 1999; DHHS publication no. (NIOSH)2000-108.
  2. Department of Labor, Occupational Safety and Health Administration. 29 CFR Part 1910.1030. Occupational exposure to bloodborne pathogens; final rule. Federal Register 1991; 56:64004–182.
  3. CDC. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39(No. RR-1).
  4. CDC. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468–72.
  5. CDC. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR 1998;47(No. RR-7).
  6. Panlilio AL, Cardo DM, Campbell S, Srivastava P, NaSH Surveillance Group. Experience of health care workers taking antiretroviral agents as postexposure prophylaxis for occupational exposure to HIV [Abstract 489]. In: Proceedings of the 1999 National HIV Prevention Conference. Atlanta, GA, 1999.
  7. Wang SA, Panlilio AL, Doi PA, et al. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV postexposure prophylaxis registry. Infect Control Hosp Epidemiol 2000;21:780–5.
  8. Puro V, Ippolito G, Italian Registry PEP. Antiretroviral post-exposure prophylaxis [Abstract 515]. In: Proceedings of the 1999 National HIV Prevention Conference. Atlanta, GA, 1999.
  9. Parkin JM, Murphy M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection [Letter]. Lancet 2000;355:722–3.
  10. Jochimsen EM, Srivastava PU, Campbell SR, Cardo DM, NaSH Surveillance Group. Postexposure prophylaxis (PEP) use among health care workers (HCWs) after occupational exposures to blood [Abstract W6-F]. In: Keynote addresses and abstracts of the 4th ICOH International Conference on Occupational Health for Health Care Workers. Montreal, Canada, 1999.
  11. Critchley SE, Srivastava PU, Campbell SR, Cardo DM, NaSH Surveillance Group. Postexposure prophylaxis use among healthcare workers who were exposed to HIV-negative source persons [Abstract P-S2-64]. In: Program and Abstracts of the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections. Atlanta, GA: CDC in conjunction with the 10th Annual Meeting of SHEA, 2000:126.
  12. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(No. RR-13).
  13. CDC. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19).
  14. CDC. Management of possible sexual, injecting-drug–use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy: Public Health Service statement. MMWR 1998;47(no. RR-17).
  15. CDC. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43(No. RR-11).
  16. CDC. Recommendations for prevention of HIV transmission in health-care settings. MMWR 1987;36(suppl no. 2S).
  17. CDC. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 1988;37:377–82,387–8.
  18. Shapiro CN, McCaig LF, Gensheimer KF, et al. Hepatitis B virus transmission between children in day care. Pediatr Infect Dis J 1989;8:870–5.
  19. Richman KM, Rickman LS. The potential for transmission of human immunodeficiency virus through human bites. J Acquir Immune Defic Syndr 1993;6:402–6.
  20. Vidmar L, Poljak M, Tomazic J, Seme K, Klavs I. Transmission of HIV-1 by human bite [Letter]. Lancet 1996;347:1762–3.
  21. CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1997;46(No. RR-18).
  22. Chiarello LA, Gerberding JL. Human immunodeficiency virus in health care settings. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Philadelphia, PA: Churchill Livingstone, 2000:3052–66.
  23. Cardo DM, Smith DK, Bell DM. Postexposure Management. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy. New York, NY: Churchill Livingstone, 1999:236–47.
  24. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev 2000;13:385–407.
  25. Mast EE, Alter MJ. Prevention of hepatitis B virus infection among health-care workers. In: Ellis RW, ed. Hepatitis B vaccines in clinical practice. New York, NY: Marcel Dekker, 1993:295–307.
  26. Werner BG, Grady GF. Accidental hepatitis-B-surface-antigen-positive inoculations: use of e antigen to estimate infectivity. Ann Intern Med 1982;97:367–9.
  27. Garibaldi RA, Hatch FE, Bisno AL, Hatch MH, Gregg MB. Nonparenteral serum hepatitis: report of an outbreak. JAMA 1972;220:963–6.
  28. Rosenberg JL, Jones DP, Lipitz LR, Kirsner JB. Viral hepatitis: an occupational hazard to surgeons. JAMA 1973;223:395–400.
  29. Callender ME, White YS, Williams R. Hepatitis B virus infection in medical and health care personnel. Br Med J 1982;284:324–6.
  30. Chaudhuri AKR, Follett EAC. Hepatitis B virus infection in medical and health care personnel [Letter]. Br Med J 1982;284:1408.
  31. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week [Letter]. Lancet 1981;1:550–1.
  32. Francis DP, Favero MS, Maynard JE. Transmission of hepatitis B virus. Semin Liver Dis 1981;1:27–32.
  33. Favero MS, Maynard JE, Petersen NJ, et al. Hepatitis-B antigen on environmental surfaces [Letter]. Lancet 1973;2:1455.
  34. Lauer JL, VanDrunen NA, Washburn JW, Balfour HH Jr. Transmission of hepatitis B virus in clinical laboratory areas. J Infect Dis 1979;140:513–6.
  35. Hennekens CH. Hemodialysis-associated hepatitis: an outbreak among hospital personnel. JAMA 1973;225:407–8.
  36. Garibaldi RA, Forrest JN, Bryan JA, Hanson BF, Dismukes WE. Hemodialysis-associated hepatitis. JAMA 1973;225:384–9.
  37. Snydman DR, Bryan JA, Macon EJ, Gregg MB. Hemodialysis-associated hepatitis: a report of an epidemic with further evidence on mechanisms of transmission. Am J Epidemiol 1976;104:563–70.
  38. Bond WW, Petersen NJ, Favero MS. Viral hepatitis B: aspects of environmental control. Health Lab Sci 1977;14:235–52.
  39. Segal HE, Llewellyn CH, Irwin G, Bancroft WH, Boe GP, Balaban DJ. Hepatitis B antigen and antibody in the U.S. Army: prevalence in health care personnel. Am J Pub Health 1976;55:667–71.
  40. Denes AE, Smith JL, Maynard JE, Doto IL, Berquist KR, Finkel AJ. Hepatitis B infection in physicians: results of a nationwide seroepidemiologic survey. JAMA 1978;239:210–2.
  41. Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol 1982;115:26–39.
  42. West DJ. The risk of hepatitis B infection among health professionals in the United States: a review. Am J Med Sci 1984;287:26–33.
  43. CDC. Recommendation of the Immunization Practices Advisory Committee (ACIP) inactivated hepatitis B virus vaccine. MMWR 1982;31:317–28.
  44. Beasley RP, Hwang L-Y, Lee G C-Y, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099–102.
  45. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA 1985;253:1740–5.
  46. Beasley RP, Hwang L-Y, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3:135–41.
  47. Grady GF, Lee VA, Prince AM, et al. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 1978;138:625–38.
  48. Seeff LB, Zimmerman HJ, Wright EC, et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis: a Veterans Administration cooperative study. Gastroenterology 1977;72:111–21.
  49. Prince AM, Szmuness W, Mann MK, et al. Hepatitis B “immune” globulin: effectiveness in prevention of dialysis-associated hepatitis. N Engl J Med 1975;293:1063–7.
  50. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Inf Dis J 1993;12:438–45.
  51. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833–41.
  52. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982;97:362–6.
  53. Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N Engl J Med 1984;311:496–501.
  54. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989;87(suppl 3A):14S–20S.
  55. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986;13(suppl A):39–45.
  56. Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA 1997;278:1176–8.
  57. Shaw FE, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination: experience of the first three years. Am J Epidemiol 1988;127:337–52.
  58. Chen D-S. Control of hepatitis B in Asia: mass immunization program in Taiwan. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore, MD: Williams and Wilkins, 1991:716–9.
  59. Niu MT, Rhodes P, Salive M, et al. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998;51:503–10.
  60. Ribera EF, Dutka AJ. Polyneuropathy associated with administration of hepatitis B vaccine [Letter]. N Engl J Med 1983;309:614–5.
  61. Tuohy PG. Guillain-Barré syndrome following immunisation with synthetic hepatitis B vaccine [Letter]. N Z Med J 1989;102:114–5.
  62. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991;338:1174–5.
  63. Gross K, Combe C, Krüger K, Schattenkirchner M. Arthritis after hepatitis B vaccination: report of three cases. Scand J Rheumatol 1995;24:50–2.
  64. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998;25:1687–93.
  65. Hassan W, Oldham R. Reiter's syndrome and reactive arthritis in health care workers after vaccination. Br Med J 1994;309:94.
  66. Grotto I, Mandel Y, Ephros M, Ashkenazi I, Shemer J. Major adverse reactions to yeast-derived hepatitis B vaccines—a review. Vaccine 1998;16:329–34.
  67. Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S, Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344:319–26.
  68. Ascherio A, Zhang SM, Hernán MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327–32.
  69. Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board. Pediatr Infect Dis J 1999;18:23–4.
  70. CDC. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR 1986;35:231–3.
  71. CDC. Outbreak of hepatitis C associated with intravenous immunoglobulin administration—United States, October 1993–June 1994, MMWR 1994;43:505–9.
  72. Ellis EF, Henney CS. Adverse reactions following administration of human gamma globulin. J Allerg 1969;43:45–54.
  73. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997;1:559–68.
  74. Lanphear BP, Linnemann CC Jr., Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994;15:745–50.
  75. Puro V, Petrosillo N, Ippolito G, Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Risk of hepatitis C seroconversion after occupational exposure in health care workers. Am J Infect Control 1995;23:273–7.
  76. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992;16:1109–14.
  77. . Sartori M, La Terra G, Aglietta M, Manzin A, Navino C, Verzetti G. Transmission of hepatitis C via blood splash into conjunctiva [Letter]. Scand J Infect Dis 1993;25:270–1.
  78. Ippolito G, Puro V, Petrosillo N, et al. Simultaneous infection with HIV and hepatitis C virus following occupational conjunctival blood exposure [Letter]. JAMA 1998;280:28.
  79. Davis GL, Lau J Y-N, Urdea MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337–41.
  80. Polish LB, Tong MJ, Co RL, Coleman PJ, Alter MJ. Risk factors for hepatitis C virus infection among health care personnel in a community hospital. Am J Infect Control 1993;21:196–200.
  81. Niu MT, Coleman PJ, Alter MJ. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis 1993;22:568–73.
  82. Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992;38:44–8.
  83. Niu MT, Alter MJ, Kristensen C, Margolis HS. Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus. Am J Kidney Dis 1992;19:345–52.
  84. Favero MS, Alter MJ. The reemergence of hepatitis B virus infection in hemodialysis centers. Semin Dial 1996;9:373–4.
  85. Knodell RG, Conrad ME, Ginsberg AL, Bell CJ, Flannery EPR. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1976;1:557–61.
  86. Sanchez-Quijano A, Pineda JA, Lissen E, et al. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1988;1:1245–9.
  87. Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996;173:822–8.
  88. Alter MJ. Occupational exposure to hepatitis C virus: a dilemma. Infect Control Hosp Epidemiol 1994;15:742–4.
  89. Peters M, Davis GL, Dooley JS, Hoofnagle JH. The interferon system in acute and chronic viral hepatitis. Progress in Liver Diseases 1986;8:453–67.
  90. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995;15:82–91.
  91. Vogel W, Graziadei I, Umlauft F, et al. High-dose interferon- 2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996;41(suppl 12):81S–85S.
  92. Quin JW. Interferon therapy for acute hepatitis C viral infection—a review by meta-analysis. Aust N Z J Med 1997;27:611–7.
  93. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455–63.
  94. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med 1997;102(suppl 5B):9–15.
  95. Ippolito G, Puro V, De Carli G, Italian Study Group on Occupational Risk of HIV Infection. The risk of occupational human immunodeficiency virus in health care workers. Arch Int Med 1993;153:1451–8.
  96. CDC. Update: human immunodeficiency virus infections in health-care workers exposed to blood of infected patients. MMWR 1987;36:285–9.
  97. Fahey BJ, Koziol DE, Banks SM, Henderson DK. Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training. Am J Med 1991;90:145–53.
  98. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures: a prospective evaluation. Ann Intern Med 1990;113:740–6.
  99. CDC. HIV/AIDS Surveillance Report. Atlanta, GA: Department of Health and Human Services, CDC, 2000:24. (vol 12, no. 1).
  100. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485–90.
  101. Mast ST, Woolwine JD, Gerberding JL. Efficacy of gloves in reducing blood volumes transferred during simulated needlestick injury. J Infect Dis 1993;168:1589–92.
  102. Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med 1997;102(suppl 5B):21–4.
  103. Clerici M, Giorgi JV, Chou C-C, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992;165:1012–9.
  104. Ranki A, Mattinen S, Yarchoan R, et al. T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989;3:63–9.
  105. Cheynier R, Langlade-Demoyen P, Marescot M-R, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol 1992;22:2211–7.
  106. Kelker HC, Seidlin M, Vogler M, Valentine FT. Lymphocytes from some long-term seronegative heterosexual partners of HIV-infected individuals proliferate in response to HIV antigens. AIDS Res Hum Retroviruses 1992;8:1355–9.
  107. Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, Oksenhendler E. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest 1994;93:1293–7.
  108. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59–64.
  109. D'Amico R, Pinto LA, Meyer P, et al. Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers. Infect Control Hosp Epidemiol 1999;20:428–30.
  110. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183:215–25.
  111. McClure HM, Anderson DC, Ansari AA, Fultz PN, Klumpp SA, Schinazi RF. Nonhuman primate models for evaluation of AIDS therapy. In: AIDS: anti-HIV agents, therapies and vaccines. Ann N Y Acad Sci 1990;616:287–98.
  112. Böttiger D, Johansson N-G, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIV sm , or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997;11:157–62.
  113. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74:9771–5.
  114. Sinet M, Desforges B, Launay O, Colin J-N, Pocidalo J-J. Factors influencing zidovudine efficacy when administered at early stages of Friend virus infection in mice. Antiviral Res 1991;16:163–71.
  115. Ruprecht RM, Bronson R. Chemoprevention of retroviral infection: success is determined by virus inoculum strength and cellular immunity. DNA Cell Biol 1994;13:59–66.
  116. Fazely F, Haseltine WA, Rodger RF, Ruprecht RM. Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon- : failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr 1991;4:1093–7.
  117. Böttiger D, Oberg B. Influence of the infectious dose of SIV on the acute infection in cynomolgus monkeys and on the effect of treatment with 3'-fluorothymidine [Abstract no. 81]. In: Symposium on Nonhuman Primate Models for AIDS. Seattle, WA, 1991.
  118. Martin LN, Murphey-Corb M, Soike KF, Davison-Fairburn B, Baskin GB. Effects of initiation of 3'-azido,3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 1993;168:825–35.
  119. Shih C-C, Kaneshima H, Rabin L, et al. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 1991;163:625–7.
  120. Mathes LE, Polas PJ, Hayes KA, Swenson CL, Johnson S, Kociba GJ. Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother 1992;36:2715–21.
  121. Tavares L, Roneker C, Johnston K, Lehrman SN, de Noronha F. 3'-azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res 1987;47:3190–4.
  122. Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2- phosphonylmethoxypropyl) adenine. Science 1995;270:1197–9.
  123. Tsai C-C, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2- phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIV mne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265–73.
  124. Le Grand R, Vaslin B, Larghero J, et al. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS 2000;14:1864–6.
  125. LaFon SW, Mooney BD, McMullen JP, et al. A double-blind, placebo-controlled study of the safety and efficacy of retrovir ® (zidovudine, ZDV) as a chemoprophylactic agent in health care workers exposed to HIV [Abstract 489]. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA: American Society for Microbiology, 1990:167.
  126. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173–80.
  127. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621–9.
  128. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999;353: 773–80.
  129. Saba J, PETRA Trial Study Team. Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1: the PETRA trial [Abstract S-7]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: Foundation for Retrovirology and Human Health in scientific collaboration with the National Institute of Allergy and Infectious Diseases and CDC, 1999.
  130. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409–14.
  131. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999;13:479–86.
  132. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795–802.
  133. Jochimsen EM. Failures of zidovudine postexposure prophylaxis. Am J Med 1997;102(suppl 5B):52–5.
  134. Pratt RD, Shapiro JF, McKinney N, Kwok S, Spector SA. Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury. J Infect Dis 1995;172:851–4.
  135. Lot F, Abiteboul D. Infections professionnelles par le V.I.H. en France chez le personnel de santé—le point au 30 juin 1995. Bulletin Épidémiologique Hebdomadiaire 1995;44:193–4.
  136. Weisburd G, Biglione J, Arbulu MM, Terrazzino JC, Pesiri A. HIV seroconversion after a work place accident and treated with zidovudine [Abstract Pub.C.1141]. In: Abstracts of the XI International Conference on AIDS. Vancouver, British Columbia, Canada, 1996:460.
  137. Perdue B, Wolderufael D, Mellors J, Quinn T, Margolick J. HIV-1 transmission by a needlestick injury despite rapid initiation of four-drug postexposure prophylaxis [Abstract 210]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: Foundation for Retrovirology and Human Health in scientific collaboration with the National Institute of Allergy and Infectious Diseases and CDC, 1999:107.
  138. Lot F, Abiteboul D. Occupational HIV infection in France [Abstract WP-25]. In: Keynote addresses and abstracts of the 4th ICOH International Conference on Occupational Health for Health Care Workers. Montreal, Canada, 1999.
  139. Beltrami EM, Luo C-C, Dela Torre N, Cardo DM. HIV transmission after an occupational exposure despite postexposure prophylaxis with a combination drug regimen [Abstract P-S2-62]. In: Program and abstracts of the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections in conjunction with the 10th Annual Meeting of SHEA. Atlanta, GA: CDC, 2000:125–6.
  140. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http://hivatis.org/ trtgdlns.html. Accessed May 9, 2001.
  141. Manion DJ, Hirsch MS. Combination chemotherapy for human immunodeficiency virus-1. Am J Med 1997;102(suppl 5B):76–80.
  142. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997;175:1051–5.
  143. Beltrami EM, Cheingsong R, Respess R, Cardo DM. Antiretroviral drug resistance in HIV-infected source patients for occupational exposures to healthcare workers [Abstract P-S2- 70]. In: Program and Abstracts of the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections. Atlanta, GA: CDC, 2000:128.
  144. Struble KA, Pratt RD, Gitterman SR. Toxicity of antiretroviral agents. Am J Med 1997;102(suppl 5B):65–7.
  145. Food and Drug Administration. Protease inhibitors may increase blood glucose in HIV patients. FDA Medical Bulletin 1997;27(2).
  146. Dever LL, Oruwari PA, O'Donovan CA, Eng RHK. Hyperglycemia associated with protease inhibitors in HIV-infected patients [Abstract LB-4]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada: American Society for Microbiology, 1997.
  147. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia [Letter]. Lancet 1997;350:713–4.
  148. Abramowicz M, ed. New drugs for HIV infection. The Medical Letter on Drugs and Therapeutics 1996;38:35–7.
  149. Martin JN, Roland ME, Bamberger JD, et al. Postexposure prophylaxis after sexual or drug use exposure to HIV: final results from the San Francisco Post-Exposure Prevention (PEP) Project [Abstract 196]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: Foundation for Retrovirology and Human Health in scientific collaboration with the National Institute of Allergy and Infectious Diseases and CDC, 2000:112.
  150. Steger KA, Swotinsky R, Snyder S, Craven DE. Recent experience with post-exposure prophylaxis (PEP) with combination antiretrovirals for occupational exposure (OE) to HIV [Abstract 480]. In: Program and abstracts of the 35th annual meeting of the Infectious Diseases Society of America. Alexandria, VA: Infectious Diseases Society of America, 1997:161.
  151. Henry K, Acosta EP, Jochimsen E. Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis [Letter]. Ann Intern Med 1996;124:855.
  152. Johnson S, Baraboutis JG; Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers [Letters]. JAMA 2000;284:2722–3.
  153. CDC. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures—worldwide, 1997–2000. MMWR 2001;49:1153–6.
  154. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS Society—USA panel. JAMA 2000;283:2417–26.
  155. Tack PC, Bremer JW, Harris AA, Landay AL, Kessler HA. Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures [Letter]. JAMA 1999;281:1085–6.
  156. CDC. Public Health Service task force recommendations for use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 1998;47(RR-2).
  157. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084–9.
  158. Smith ME, US Nucleoside Safety Review Working Group. Ongoing nucleoside safety review of HIV exposed children in US studies [Abstract 96]. In: Final program and abstracts for the Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, Canada: New York Academy of Sciences, 1999:49.
  159. Food and Drug Administration. Important drug warning. Available at http://www.fda.gov/ medwatch/safety/2001/zerit&videx_letter.htm. Accessed May 9, 2001.
  160. Veeder AV, McErlean M, Putnam K, Caldwell WC, Venezia RA. The impact of a rapid HIV test to limit unnecessary post exposure prophylaxis following occupational exposures [Abstract P-S2-66]. In: Program and Abstracts of the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections in conjunction with the 10th Annual Meeting of SHEA. Atlanta, GA: CDC, 2000:127.
  161. CDC. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989;38(No. S-6).
  162. Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996;17:54–80.
  163. CDC. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. MMWR 1991;40(No. RR-8).
  164. Coursaget P, Yvonnet B, Relyveld EH, Barres JL, Diop-Mar I, Chiron JP. Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen. Infect Immun 1986;51:784–7.
  165. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209–14.
  166. CDC. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991;40(No. RR-4):1–17.
  167. Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997;336:919–22.
  168. Ciesielski CA, Metler RP. Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Am J Med 1997;102(suppl 5B):115–6.
  169. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997;102(suppl 5B):117–24.
  170. Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med 1999;130:37–9.
  171. Roland ME, Elbeik TA, Martin JN, et al. HIV-1 RNA testing by bDNA and PCR in asymptomatic patients following sexual exposure to HIV [Abstract 776]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: Foundation for Retrovirology and Human Health in scientific collaboration with the National Institute of Allergy and Infectious Diseases and CDC, 2000:220.
  172. Gerberding JL, Henderson DK. Management of occupational exposures to bloodborne pathogens: hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Clin Inf Dis 1992;14:1179–85.
  173. Armstrong K, Gorden R, Santorella G. Occupational exposures of health care workers (HCWs) to human immunodeficiency virus (HIV): stress reactions and counseling interventions. Soc Work Health Care 1995;21:61–80.
  174. Henry K, Campbell S, Jackson B, et al. Long-term follow-up of health care workers with work-site exposure to human immunodeficiency virus [Letter]. JAMA 1990;263:1765.
  175. AIDS/TB Committee of the Society for Healthcare Epidemiology of America. Management of healthcare workers infected with hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or other bloodborne pathogens. Infect Control Hosp Epidemiol 1997;18:349–63




Copyright © 2001-2002. The National AIDS Education and Training Centers Program on behalf of its AETC National Resource Center. All rights reserved.

Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need, and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.